Size | Price | Stock | Qty |
---|---|---|---|
2g |
|
||
5g |
|
||
10g |
|
||
50g |
|
||
100g |
|
||
200g |
|
||
Other Sizes |
|
Purity: ≥98%
Folic acid (also known as Vitamin M; Vitamin B9; folate) is a one of the B vitamins and is necessary for the production and maintenance of new cells, for DNA synthesis and RNA synthesis. The synthesis of DNA, RNA, and the metabolism of amino acids—which are necessary for cell division—require folate, which is found in different forms as folic acid, folacin, and vitamin B9. Folate is a necessary vitamin because humans cannot produce it; therefore, it must come from food. Intake of 400 micrograms of folate per day from food or dietary supplements is advised for adults in the United States.
Targets |
Human Endogenous Metabolite; Microbial Metabolite
|
---|---|
ln Vitro |
Folic acid treatment increases the expression of BRCA1 mRNA in HepG2, Huh-7D12, Hs578T, and JURKAT cells and BRCA2 mRNA in HepG2, Hs578T, MCF7, and MDA-MB-157 cells in a dose-dependent manner. FA has no effect on any of the ovarian cell lines or the corresponding normal cells. In Hs578T cells, folic acid increases BRCA1 protein expression but not HepG2 cell expression; BRCA2 protein expression is not detected. While there are short-term effects on breast-derived cells, FA treatment has no effect on DNA repair in liver-derived cells. FA treatment has no effect on the methylation of the BRCA1 or BRCA2 DNA, however some cell lines have different levels of methylation at particular CpG loci[1].
|
ln Vivo |
No folic acid (1, 5 mg/kg; interface) prevents epigenetic modifications of gene expression in chromosomal offspring in mice adapted to a new environment [3]. Folic acid (10, 50, 100 mg/kg; side) exhibits antidepressant-like effects in this behavioral mouse model [2].
|
Cell Assay |
All cell lines were treated with 0, 25, 50, 75, or 100 nmol/L FA for 72 hours prior to harvesting in TRI Reagent in accordance with the manufacturer's instructions in order to ascertain the impact of FA supplementation on BRCA1 and BRCA2 mRNA expression.
|
Animal Protocol |
Animal/Disease Models: 30-40 g Swiss mice [2]
Doses: 10, 50, 100 mg/kg Route of Administration: Oral Experimental Results: diminished immobility time in the forced swim test (FST) (F324=11.21), and Immobility time in the tail suspension test (TST) had a significant effect (F3, 20=5.71). Animal/Disease Models: 30-40 g Swiss mice [2] Doses: 1-10 nmol/site Route of Administration: Intracerebroventricular injection Experimental Results: diminished mouse FST (F3,22=12.31) and TST (F3,22=5.50) immobile time). Animal/Disease Models: Virgin female Wistar rats [3] Doses: 1, 5 mg/kg (180 g/kg protein plus 1 mg/kg folic acid or 90 g/kg casein plus 1, 5 mg/kg folic acid) Route of Administration: Oral administration Experimental Results: Prevention of epigenetic modifications in liver gene expression in offspring. |
References |
[1]. Butterworth CE Jr, et al. Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989 Aug;50(2):353-8.
[2]. Brocardo PS, et al. Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology. 2008 Feb;54(2):464-73. [3]. Lillycrop KA, et al. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr. 2005 Jun;135(6):1382-6. [4]. Pietrzik K, et al. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010 Aug;49(8):535-48. |
Molecular Formula |
C19H19N7O6
|
---|---|
Molecular Weight |
441.3975
|
Exact Mass |
441.14
|
Elemental Analysis |
C, 51.70; H, 4.34; N, 22.21; O, 21.75
|
CAS # |
59-30-3
|
Related CAS # |
70114-87-3 (Folic acid, methyl-); 134-05-4 (10-Formylfolic acid); 54931-98-5 (10-Thiofolic acid); 119770-54-6 (11-Deazahomofolic acid); 72254-43-4 (11-Oxahomofolic acid); 85597-18-8 ( 5,10-Dideazafolic acid); 111113-75-8 (5,6,7,8-Tetrahydro-8-deazahomofolic acid); 130327-67-2 ( 5-Deazaisofolic acid); 51989-25-4 ( 8-Deazafolic acid; NSC 173522); 111113-73-6 (8-Deazahomofolic acid); 14866-11-6 (Dihydrohomofolic acid); 83704-88-5 (HH-Folic acid is a derivative of vitamin B); 3566-25-4 (Homofolic acid); 11076-68-9 (Lyofolic acid); 29291-35-8 (Nitrosofolic acid; CCRIS 466); 88912-57-6 (Pyrrofolic acid); 135-16-0 (5,6,7,8-tetrahydrofolic acid; Tetrahydropteroylglutamic acid; th-folate; folate-H4); 5786-82-3 (Tetrahydrohomofolic acid); 52454-37-2 (10-Deazaaminopterin; 10-Deaza-aminopterin; NSC 311469; NSC-311469; NSC311469); 28459-40-7 (10-Formyldihydrofolate); 2800-34-2 (10-Formyltetrahydrofolic acid; 10-Formyl-THF; 10FTHF); 74163-10-3 ( 11-Thiohomoaminopterin, a close analog of 11-thiohomofolic acid); 85803-29-8 (2-Fluoroaminopterin); 5472-96-8 (3-Chloromethotrexate); 59904-24-4 (5-Methyldihydrofolate); 50998-20-4 (5-Methyltetrahydrofolate triglutamate); 73951-54-9 (6R-Leucovorin); 77739-71-0 (Acanthifolicin); 25312-31-6 (Aminoanfol, an antifolic acid compound); 31690-11-6 (Arfolitixorin free, an antifolate modulator); 149930-93-8 (Arfolitixorin sulfate); 154705-24-5 (Arfolitixorin sodium); 501332-69-0 (BGC-945); 115940-48-2 (Calcium dextrofolinate, calcium salt of a derivative of Folic Acid);26560-38-3 (Calcium methyltetrahydrofolate); 5854-11-5 (CB 3705; CB-3705; CB3705; 5,8-Dideazafolic acid); 76849-19-9 (CB 3717; CB-3717; CB3717; N(sup 10)-Propargyl-5,8-dideazafolic acid); 18921-73-8 (chlorasquin, an inhibitor of dihydrofolate reductase); 4033-27-6 (Dihydrofolate); 36093-88-6 (Dihydroaminopterin); 528-74-5 (Dichloromethotrexate); 6807-82-5 ( Diopterin, a folic acid analog); 1148151-21-6 [Folitixorin calcium, (6R)-]; 6484-89-5 (Folate sodium; Folvite sodium); 815587-59-8 [olitixorin calcium, (6S)-]; 133978-76-4 (Folitixorin sodium); 35409-55-3 (Hexaglutamate folate); 112887-62-4 (ICI 198583, an antifolate thymidylate synthase inhibitor); 31690-09-2 (Levomefolinic acid); 1423663-76-6 ( Levomefolate sodium); 1429498-11-2 ( Levomefolate magnesium); 58-05-9 ( Levoleucovorin free acid); 1492-18-8 ( Levoleucovorin calcium); 6035-45-6 ( Levoleucovorin calcium hydrate); 163254-40-8 ( Levoleucovorin sodium); 1141892-29-6 (Levoleucovorin sodium); 120408-07-3 (Lometrexol sodium); 106400-81-1 (Lometrexol free acid); 106400-18-4 (LY249543, the S-isomer of lometrexol); 136208-85-0 (LY249543, the S-isomer of lometrexol); 82339-36-4 (Lysine-iodoacetylmethotrexate, a Folic Acid Antagonist); 7413-34-5 ( Methotrexate disodium); 7532-09-4 (Methotrexate monosodium); 59-05-2 (Methotrexate free acid); 6745-93-3 (Methotrexate hydrate); 15475-56-6 (Methotrexate sodium); 66147-29-3 (Methotrexate 1-methyl ester); 67022-39-3 (Methotrexate 5-methyl este); 79573-48-1 (Mefox; (6RS)-Mefox); 2179-16-0 (Ninopterin); 41600-13-9 (NSC269401, the isotope labelled analog of Methotrexate Diglutamate; 41600-14-0 ( NSC341076 is the isotope labelled analog of Methotrexate Triglutamate); 2197232-28-1 (OSI-7904L,1843U89; racemic) 139987-54-5 (OSI-7904L,1843U89; free acid); 89-38-3 (Pteropterin); 6164-84-7 (Pteropterin monohydrate); 33611-85-7 ( Pteroylpentaglutamic acid); 112887-68-0 (Raltitrexed); 4299-28-9 (Tetrahydromethotrexate); 29701-38-0 (Triglutamate folate); 52128-35-5 (Trimetrexate)
|
Appearance |
Solid powder
|
SMILES |
C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
|
InChi Key |
OVBPIULPVIDEAO-LBPRGKRZSA-N
|
InChi Code |
InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
|
Chemical Name |
(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
|
Synonyms |
FA; N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid; pteroyl-L-glutamic acid; folacin; pteroyl-L-glutamate; Folic acid; Vitamin B11; Vitamin B9; Vitamin Bc; Vitamin Be; Vitamin M
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
1M NaOH: ~100 mg/mL (~226.6 mM)
DMSO: ~33.3 mg/mL (~75.5 mM) H2O: < 0.1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.71 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2655 mL | 11.3276 mL | 22.6552 mL | |
5 mM | 0.4531 mL | 2.2655 mL | 4.5310 mL | |
10 mM | 0.2266 mL | 1.1328 mL | 2.2655 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03853304 | Active Recruiting |
Other: + Folic acid Other: + Vitamin B12 |
Anemia Folate Deficiency |
Cornell University | October 1, 2023 | Not Applicable |
NCT05959044 | Recruiting | Drug: Folic Acid Tablet Other: Placebo |
Parkinson Disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
April 16, 2023 | Phase 2 |
NCT05296369 | Recruiting | Drug: Folic acid | Lung Cancer | Guizhou Medical University | March 1, 2022 | Not Applicable |
NCT06010277 | Recruiting | Drug: Folinic acid | NSCLC Thymoma |
Amphia Hospital | February 6, 2023 | Phase 4 |
NCT03837977 | Active Recruiting |
Drug: Folinic Acid Drug: Docetaxel |
Neuroendocrine Carcinoma Oncology |
The Christie NHS Foundation Trust | November 13, 2018 | Phase 2 |